US7351699B1ExpiredUtility

Use of DHEA or precursors or metabolic derivatives thereof as a depigmenting agent

43
Assignee: OREALPriority: Oct 13, 1999Filed: Oct 12, 2000Granted: Apr 1, 2008
Est. expiryOct 13, 2019(expired)· nominal 20-yr term from priority
Inventors:Olivier De LacharriereStephanie Nouveau
A61P 43/00A61K 8/40A61Q 19/00A61K 8/35A61K 8/63A61K 8/466A61K 8/368A61P 17/00A61Q 19/02A61P 17/12A61K 8/4946A61K 8/585A61K 8/37
43
PatentIndex Score
0
Cited by
56
References
25
Claims

Abstract

The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation regulator for the skin or its superficial growths, especially as a depigmenting and/or bleaching agent for the skin, in particular in the treatment of pigmentation marks, and as a pro-pigmenting agent for superficial body growths.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A method of pro-pigmenting human hair in need of pro-pigmenting, comprising applying DHEA or at least one biological precursor thereof or metabolic derivative thereof to the human hair, wherein said metabolic derivative thereof is selected from the group consisting of 5-androstene-3β,17β-diol, 5-androstene-3β,17β-diol sulfate and 4-androstene-3,17-dione and said biological precursor thereof is selected from the group consisting of pregnenolone, 17α-hydroxypregnenolone, DHEA sulfate, and 17α-hydroxypregnenolone sulfate. 
     
     
       2. The method of  claim 1 , wherein the DHEA or at least one of biological precursor thereof or metabolic derivative thereof is applied in the form of a composition. 
     
     
       3. The method of  claim 1 , wherein the DHEA or at least one biological precursor thereof or metabolic derivative thereof is applied in the form of a composition comprising from 10 −6 % to 10% by weight, relative to the total weight of the composition, of the DHEA or at least one of biological precursor thereof or metabolic derivative thereof. 
     
     
       4. The method of  claim 3 , wherein the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the DHEA or at least one biological precursor thereof or metabolic derivative thereof. 
     
     
       5. The method of  claim 3 , wherein the composition comprises about 1% by weight, relative to the total weight of the composition, of the DHEA or at least one biological precursor thereof or metabolic derivative thereof. 
     
     
       6. The method of  claim 2 , wherein the composition further comprises at least one UV screening agent and/or one depigmenting agent and/or one keratolytic agent. 
     
     
       7. The method of  claim 6 , wherein the composition further comprises the UV screening agent selected from the group consisting of dibenzoylmethane derivatives, benzylidenecamphor-based UVA-active screening agents, benzylidenecamphor-based UVB-active screening agents, benzimidazole-type or benzoxazole-type UVA-active screening agents, benzophenone derivatives, silane derivatives, polyorganosiloxanes containing a benzophenone group, benzotriazoles, benzotriazole silicones, triazine derivatives, cinnamic acid derivatives, alkyl 2-cyano-3,3-diphenylacrylates, octocrylene, the compound of formula I below, 
       
         
           
           
               
               
           
         
       
       and mixtures thereof. 
     
     
       8. The method of  claim 6 , wherein the composition further comprises said depigmenting agent selected from the group consisting of kojic acid, ellagic acid, arbutin and derivatives thereof, hydroquinone, aminophenol derivatives, iminophenol derivatives, L-2-oxothiazolidone-4-carboxylic acid and salts or esters thereof, procysteine and salts or esters thereof, ascorbic acid and derivatives thereof, and plant extracts. 
     
     
       9. The method of  claim 6 , wherein the composition further comprises said keratolytic agent selected from the group consisting of α-hydroxy acids, β-hydroxy acids, α-keto acids, β-keto acids, retinoids, HMG-COA reductase inhibitor, and sugar derivatives. 
     
     
       10. The method of  claim 1 , comprising applying DHEA to the human superficial body growths. 
     
     
       11. The method of  claim 1 , comprising applying 5-androstene-3β,17β-diol to the human superficial body growths. 
     
     
       12. The method of  claim 1 , comprising applying 5-androstene-3β,17β-diol sulfate to the human superficial body growths. 
     
     
       13. The method of  claim 1 , comprising applying 4-androstene-3,17-dione to the human superficial body growths. 
     
     
       14. The method of  claim 1 , comprising applying pregnenolone to the human superficial body growths. 
     
     
       15. The method of  claim 1 , comprising applying 17α-hydroxypregnenolone to the human superficial body growths. 
     
     
       16. The method of  claim 1 , comprising applying DHEA sulfate to the human superficial body growths. 
     
     
       17. The method of  claim 1 , comprising applying 17α-hydroxypregnenolone sulfate to the human superficial body growths. 
     
     
       18. The method of  claim 10 , wherein the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the DHEA. 
     
     
       19. The method of  claim 11 , wherein the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the 5-androstene-3β,17β-diol. 
     
     
       20. The method of  claim 12 , wherein the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the 5-androstene-3β,17β-diol sulfate. 
     
     
       21. The method of  claim 13 , wherein the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the 4-androstene-3,17-dione. 
     
     
       22. The method of  claim 14 , wherein the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the pregnenolone. 
     
     
       23. The method of  claim 15 , wherein the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the 17α-hydroxypregnenolone. 
     
     
       24. The method of  claim 16 , wherein the the DHEA sulfate is applied in the form of a composition, and the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the DHEA sulfate. 
     
     
       25. The method of  claim 17 , wherein the composition comprises from 0.1% to 5% by weight, relative to the total weight of the composition, of the 17α-hydroxypregnenolone sulfate.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.